vs
Eventbrite, Inc.（EB）与MESA LABORATORIES INC（MLAB）财务数据对比。点击上方公司名可切换其他公司
Eventbrite, Inc.的季度营收约是MESA LABORATORIES INC的1.1倍（$73.5M vs $65.1M），MESA LABORATORIES INC净利率更高（5.6% vs -11.1%，领先16.7%），MESA LABORATORIES INC同比增速更快（3.6% vs -3.9%），MESA LABORATORIES INC自由现金流更多（$18.0M vs $-60.9M），过去两年MESA LABORATORIES INC的营收复合增速更高（5.1% vs -7.7%）
Eventbrite是源自美国的线下活动服务平台，为用户提供活动浏览、创建与推广服务，支持主办方免费在平台发布不限规模、不限数量的各类活动，是全球范围内活跃度较高的活动交易与推广平台。
梅萨实验室有限公司开发、生产和销售专业质控、校准及监测仪器与配套服务，核心业务覆盖医疗健康、制药、食品饮料、工业卫生及环境检测领域，为全球客户满足合规及运营安全需求提供支持。
EB vs MLAB — 直观对比
营收规模更大
EB
是对方的1.1倍
$65.1M
营收增速更快
MLAB
高出7.5%
-3.9%
净利率更高
MLAB
高出16.7%
-11.1%
自由现金流更多
MLAB
多$78.9M
$-60.9M
两年增速更快
MLAB
近两年复合增速
-7.7%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $73.5M | $65.1M |
| 净利润 | $-8.2M | $3.6M |
| 毛利率 | 68.1% | 64.2% |
| 营业利润率 | -12.4% | 12.2% |
| 净利率 | -11.1% | 5.6% |
| 营收同比 | -3.9% | 3.6% |
| 净利润同比 | 2.5% | 316.6% |
| 每股收益（稀释后） | $-0.08 | $0.65 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EBMLAB
| Q4 25 | $73.5M | $65.1M | ||
| Q3 25 | $71.7M | $60.7M | ||
| Q2 25 | $72.8M | $59.5M | ||
| Q1 25 | $73.8M | $62.1M | ||
| Q4 24 | $76.5M | $62.8M | ||
| Q3 24 | $77.8M | $57.8M | ||
| Q2 24 | $84.6M | $58.2M | ||
| Q1 24 | $86.3M | $58.9M |
净利润EBMLAB
| Q4 25 | $-8.2M | $3.6M | ||
| Q3 25 | $6.4M | $2.5M | ||
| Q2 25 | $-2.1M | $4.7M | ||
| Q1 25 | $-6.6M | $-7.1M | ||
| Q4 24 | $-8.4M | $-1.7M | ||
| Q3 24 | $-3.8M | $3.4M | ||
| Q2 24 | $1.1M | $3.4M | ||
| Q1 24 | $-4.5M | $-254.6M |
毛利率EBMLAB
| Q4 25 | 68.1% | 64.2% | ||
| Q3 25 | 67.9% | 61.5% | ||
| Q2 25 | 67.5% | 62.0% | ||
| Q1 25 | 66.9% | 61.8% | ||
| Q4 24 | 68.2% | 63.3% | ||
| Q3 24 | 68.5% | 61.3% | ||
| Q2 24 | 70.9% | 64.0% | ||
| Q1 24 | 71.0% | 62.1% |
营业利润率EBMLAB
| Q4 25 | -12.4% | 12.2% | ||
| Q3 25 | -1.3% | 7.8% | ||
| Q2 25 | -8.7% | 5.1% | ||
| Q1 25 | -13.2% | 2.4% | ||
| Q4 24 | -10.2% | 9.2% | ||
| Q3 24 | -11.5% | 6.1% | ||
| Q2 24 | -7.6% | 9.6% | ||
| Q1 24 | -8.8% | -460.6% |
净利率EBMLAB
| Q4 25 | -11.1% | 5.6% | ||
| Q3 25 | 8.9% | 4.1% | ||
| Q2 25 | -2.9% | 8.0% | ||
| Q1 25 | -9.0% | -11.4% | ||
| Q4 24 | -11.0% | -2.7% | ||
| Q3 24 | -4.8% | 5.9% | ||
| Q2 24 | 1.3% | 5.8% | ||
| Q1 24 | -5.2% | -432.2% |
每股收益（稀释后）EBMLAB
| Q4 25 | $-0.08 | $0.65 | ||
| Q3 25 | $0.06 | $0.45 | ||
| Q2 25 | $-0.02 | $0.85 | ||
| Q1 25 | $-0.07 | $-1.30 | ||
| Q4 24 | $-0.09 | $-0.31 | ||
| Q3 24 | $-0.04 | $0.63 | ||
| Q2 24 | $0.01 | $0.62 | ||
| Q1 24 | $-0.05 | $-47.26 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $299.9M | $29.0M |
| 总债务越低越好 | $144.4M | $68.4M |
| 股东权益账面价值 | $179.1M | $186.7M |
| 总资产 | $647.2M | $434.8M |
| 负债/权益比越低杠杆越低 | 0.81× | 0.37× |
8季度趋势，按日历期对齐
现金及短期投资EBMLAB
| Q4 25 | $299.9M | $29.0M | ||
| Q3 25 | — | $20.4M | ||
| Q2 25 | — | $21.3M | ||
| Q1 25 | — | $27.3M | ||
| Q4 24 | $441.5M | $27.3M | ||
| Q3 24 | $24.7M | $24.3M | ||
| Q2 24 | $56.7M | $28.5M | ||
| Q1 24 | $113.7M | $28.2M |
总债务EBMLAB
| Q4 25 | $144.4M | $68.4M | ||
| Q3 25 | $174.9M | $69.4M | ||
| Q2 25 | $241.3M | $70.3M | ||
| Q1 25 | $241.0M | $71.3M | ||
| Q4 24 | $240.7M | $72.2M | ||
| Q3 24 | $240.4M | $73.1M | ||
| Q2 24 | $358.7M | $74.1M | ||
| Q1 24 | $358.2M | — |
股东权益EBMLAB
| Q4 25 | $179.1M | $186.7M | ||
| Q3 25 | $189.1M | $178.5M | ||
| Q2 25 | $177.2M | $172.5M | ||
| Q1 25 | $173.3M | $159.8M | ||
| Q4 24 | $170.2M | $155.2M | ||
| Q3 24 | $179.8M | $161.5M | ||
| Q2 24 | $176.2M | $150.7M | ||
| Q1 24 | $184.1M | $145.4M |
总资产EBMLAB
| Q4 25 | $647.2M | $434.8M | ||
| Q3 25 | $744.6M | $430.4M | ||
| Q2 25 | $784.1M | $435.7M | ||
| Q1 25 | $812.3M | $433.3M | ||
| Q4 24 | $752.3M | $433.3M | ||
| Q3 24 | $817.4M | $454.1M | ||
| Q2 24 | $894.5M | $440.4M | ||
| Q1 24 | $952.2M | $446.8M |
负债/权益比EBMLAB
| Q4 25 | 0.81× | 0.37× | ||
| Q3 25 | 0.92× | 0.39× | ||
| Q2 25 | 1.36× | 0.41× | ||
| Q1 25 | 1.39× | 0.45× | ||
| Q4 24 | 1.41× | 0.47× | ||
| Q3 24 | 1.34× | 0.45× | ||
| Q2 24 | 2.04× | 0.49× | ||
| Q1 24 | 1.95× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-60.8M | $18.8M |
| 自由现金流经营现金流 - 资本支出 | $-60.9M | $18.0M |
| 自由现金流率自由现金流/营收 | -82.8% | 27.7% |
| 资本支出强度资本支出/营收 | 0.0% | 1.1% |
| 现金转化率经营现金流/净利润 | — | 5.17× |
| 过去12个月自由现金流最近4个季度 | $17.6M | $37.9M |
8季度趋势，按日历期对齐
经营现金流EBMLAB
| Q4 25 | $-60.8M | $18.8M | ||
| Q3 25 | $36.7M | $8.2M | ||
| Q2 25 | $-17.5M | $1.9M | ||
| Q1 25 | $59.4M | $12.7M | ||
| Q4 24 | $-45.3M | $18.1M | ||
| Q3 24 | $44.6M | $5.3M | ||
| Q2 24 | $-32.3M | $10.7M | ||
| Q1 24 | $68.6M | $12.9M |
自由现金流EBMLAB
| Q4 25 | $-60.9M | $18.0M | ||
| Q3 25 | $36.6M | $7.1M | ||
| Q2 25 | $-17.5M | $884.0K | ||
| Q1 25 | $59.4M | $11.9M | ||
| Q4 24 | $-45.3M | $17.3M | ||
| Q3 24 | $44.4M | $3.5M | ||
| Q2 24 | $-32.4M | $9.9M | ||
| Q1 24 | $68.2M | $12.3M |
自由现金流率EBMLAB
| Q4 25 | -82.8% | 27.7% | ||
| Q3 25 | 51.1% | 11.7% | ||
| Q2 25 | -24.1% | 1.5% | ||
| Q1 25 | 80.4% | 19.2% | ||
| Q4 24 | -59.2% | 27.6% | ||
| Q3 24 | 57.1% | 6.0% | ||
| Q2 24 | -38.3% | 16.9% | ||
| Q1 24 | 79.1% | 21.0% |
资本支出强度EBMLAB
| Q4 25 | 0.0% | 1.1% | ||
| Q3 25 | 0.0% | 1.8% | ||
| Q2 25 | 0.0% | 1.7% | ||
| Q1 25 | 0.1% | 1.2% | ||
| Q4 24 | 0.0% | 1.3% | ||
| Q3 24 | 0.2% | 3.1% | ||
| Q2 24 | 0.1% | 1.5% | ||
| Q1 24 | 0.4% | 0.9% |
现金转化率EBMLAB
| Q4 25 | — | 5.17× | ||
| Q3 25 | 5.76× | 3.32× | ||
| Q2 25 | — | 0.40× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.54× | ||
| Q2 24 | -30.37× | 3.17× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EB
| US | $52.0M | 71% |
| Other | $21.6M | 29% |
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
